NCT06382987 (RePhlect) is a clinical trial of Deucravacitinib in Plaque Psoriasis, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT06382987?

NCT06382987 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT06382987?

Interventions in NCT06382987: Deucravacitinib, Apremilast.

What condition does NCT06382987 study?

NCT06382987 studies Plaque Psoriasis.

Is NCT06382987 still recruiting?

NCT06382987 is currently recruiting now. Last updated 25 April 2024.

Last reviewed 2024-04-25 · How we verify

NCT06382987: RePhlect

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

Recruiting now Last updated 25 April 2024

What this trial tests

trial testing Deucravacitinib in Plaque Psoriasis in 600 participants. Currently enrolling.

Timeline

22 January 2024

Primary endpoint
31 December 2029

31 December 2029

Quick facts

Lead sponsor	Bristol-Myers Squibb
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	600
Start date	22 January 2024
Primary completion	31 December 2029
Estimated completion	31 December 2029
Sites	2 locations across Japan

Drugs / interventions tested

Deucravacitinib (DEUCRAVACITINIB) — full drug profile →
Apremilast (APREMILAST) — full drug profile →

Conditions studied

Plaque Psoriasis — all drugs for Plaque Psoriasis →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

18 and older, any sex, with Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

New and emerging oral therapies for psoriasis.
Yilmaz O, Pinto JP, Torres T. · · 2024 · cited 3× · PMID 39131603 · DOI 10.7573/dic.2024-5-6

Verify or expand the search:

Other trials of Deucravacitinib

Trials testing the same drug.

NCT07280702 — Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease · Phase 4 · not yet recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting
NCT07256015 — Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy · recruiting

Other recruiting trials for Plaque Psoriasis

Currently open trials in the same condition.

NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor · Phase 3 · recruiting
NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis · Phase 3 · recruiting
NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06382987 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 25 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06382987.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing